Aigen Investment Management’s TG Therapeutics TGTX Stock Holding History

Aigen Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	+4,205	New	+$172K	0.06%	395
2025 Q2	–	Sell	-9,522	Closed	-$375K	–	1066
2025 Q1	$375K	Buy	+9,522	New	+$320K	0.06%	423
2024 Q3	–	Sell	-18,464	Closed	-$328K	–	1010
2024 Q2	$328K	Buy	18,464 +2,292	+14%	+$36.6K	0.06%	447
2024 Q1	$246K	Buy	+16,172	New	+$258K	0.05%	492
2023 Q4	–	Sell	-94,748	Closed	-$792K	–	1081
2023 Q3	$792K	Buy	94,748 +83,783	+764%	+$1.17M	0.15%	219
2023 Q2	$272K	Sell	10,965 -4,772	-30%	-$123K	0.04%	522
2023 Q1	$237K	Buy	+15,737	New	+$239K	0.03%	488
2021 Q1	–	Sell	-16,246	Closed	-$845K	–	878
2020 Q4	$845K	Buy	+16,246	New	+$549K	0.11%	245

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Aigen Investment Management's TGTX Position: Q2 2026 in Review

Aigen Investment Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,205 shares worth $231K. The stake represents 0.06% of the portfolio and ranks #395 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in TGTX as recently as Q1 2025.

Aigen Investment Management first reported a position in TGTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $845K in Q4 2020. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Aigen Investment Management held 4,205 shares of TG Therapeutics worth $231K as of Q2 2026.
TG Therapeutics was a new Aigen Investment Management position in Q2 2026.
TG Therapeutics made up 0.06% of Aigen Investment Management's portfolio in Q2 2026, its #395 holding.
Aigen Investment Management first reported a position in TG Therapeutics in Q4 2020 and has held it in 8 quarters since.
Aigen Investment Management's TG Therapeutics position peaked at $845K in Q4 2020.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.